Wells Fargo Maintains Tenet Healthcare(THC.US) With Buy Rating, Maintains Target Price $175
Barclays Maintains Tenet Healthcare(THC.US) With Buy Rating, Maintains Target Price $171
Barclays Keeps Their Buy Rating on Tenet Healthcare (THC)
BofA Securities Maintains Tenet Healthcare(THC.US) With Buy Rating
Bank of America Securities Sticks to Their Buy Rating for Tenet Healthcare (THC)
Tenet Healthcare Analyst Ratings
Tenet Healthcare Analyst Ratings
J.P. Morgan Sticks to Its Buy Rating for Tenet Healthcare (THC)
Jefferies Maintains Tenet Healthcare(THC.US) With Buy Rating, Raises Target Price to $175
Truist Financial Remains a Buy on Tenet Healthcare (THC)
Truist Financial Maintains Tenet Healthcare(THC.US) With Buy Rating
Wells Fargo Maintains Tenet Healthcare(THC.US) With Buy Rating, Maintains Target Price $175
Strategic Divestiture Enhances Tenet Healthcare's Equity Value: Buy Rating Affirmed
Wells Fargo Maintains Tenet Healthcare(THC.US) With Buy Rating, Raises Target Price to $175
Tenet Healthcare (THC) Receives a Buy From Wells Fargo
Tenet Healthcare Analyst Ratings
Barclays Maintains Tenet Healthcare(THC.US) With Buy Rating, Raises Target Price to $171
Tenet Healthcare (THC) Gets a Buy From Barclays
Buy Rating Affirmed for Tenet Healthcare on Strong Financials and Growth Prospects
Tenet Healthcare Price Target Raised to $168.00/Share From $112.00 by Cantor Fitzgerald